Search CatalystAlert
Search for companies, drugs, and catalysts
Search CatalystAlert
Search for companies, drugs, and catalysts
Search for companies, drugs, and catalysts
Search for companies, drugs, and catalysts
Pharmaceutical Preparations · market cap $465M
Research and calibrated estimates, not financial advice — verify before acting.
| Asset | Phase | Indication |
|---|---|---|
| PROVARIX | Phase 3 | Varicella (Chickenpox) |
| 36-71 months old children-experimental EV71 vaccine. | Phase 3 | Hand, Foot and Mouth Disease |
| investigational 23-valent PPV | Phase 3 | Pneumococcal Infections |
| 400U /0.5ml EV71 vaccine | Phase 3 | Hand, Foot and Mouth Disease |
| Investigational sIPV | Phase 3 | Poliomyelitis |
| three consecutive lots of EV71 vaccine | Phase 3 | Hand, Foot and Mouth Disease |
| Three doses of experimental sIPV of lot 1 at the schedule of 2,3,4 months of age | Phase 3 | Poliomyelitis |
| Quadrivalent influenza vaccine | Phase 3 | Seasonal Influenza |
| Single-dose regimen of high dosage investigational sIPV | Phase 2 | Poliomyelitis |
| sIPV-sIPV-bOPV vaccination schedule | Phase 3 | Poliomyelitis |
| Trivalent influenza vaccine (contains B/Victoria strain) | Phase 3 | Seasonal Influenza |
| pandemic influenza vaccine (H5N1 strain NIBRG-14) | Phase 2 | Pandemic Influenza |
| 100U EV71 vaccine with adjuvant | Phase 2 | Infection, Viral, Enterovirus |
| sIPV-bOPV-bOPV vaccination schedule | Phase 3 | Poliomyelitis |
| split-virion pandemic influenza vaccine (H5N1 strain NIBRG-14) | Phase 2 | Influenza |
| Quadrivalent influenza vaccine(0.5ml) | Phase 3 | Seasonal Influenza |
| Influenza Vaccine (Split Virion), Inactivated, Quadrivalent | Phase 3 | Seasonal Influenza |
| Experimental vaccine | Phase 3 | Poliomyelitis |
| Quadrivalent influenza vaccine(0.25ml) | Phase 3 | Seasonal Influenza |
| bivalent enterovirus vaccine (Vero cell), inactivated | Phase 3 | Hand, Foot, and Mouth Disease（HFMD) |
Daily closes through 2026-07-02. Realized vol annualized; max drawdown over ~2 years.
The full dossier is a Pro feature
Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.
See ProApproval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.
Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, Financial Modeling Prep). Compiled by CeliA. Not financial advice.